Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

NCT05301842 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

760

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Tremelimumab
DRUG: Durvalumab
PROCEDURE: Transarterial Chemoembolization (TACE)
DRUG: Lenvatinib

Sponsor

AstraZeneca